Last reviewed · How we verify

Placebo with enzalutamide — Competitive Intelligence Brief

Placebo with enzalutamide (Placebo with enzalutamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist. Area: Oncology.

phase 3 Androgen receptor antagonist Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo with enzalutamide (Placebo with enzalutamide) — Pfizer. Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, thereby suppressing androgen-driven prostate cancer cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo with enzalutamide TARGET Placebo with enzalutamide Pfizer phase 3 Androgen receptor antagonist Androgen receptor (AR)
Maximum androgen blockade Maximum androgen blockade Wonju Severance Christian Hospital marketed Androgen receptor antagonist combination therapy Androgen receptor; testosterone synthesis pathway
Darolutamide Oral Tablet Darolutamide Oral Tablet Santa Chiara Hospital marketed Androgen receptor antagonist Androgen receptor (AR)
ODM-201 Tablet A ODM-201 Tablet A Orion Corporation, Orion Pharma marketed Androgen receptor antagonist Androgen receptor (AR)
Zoladex and Casodex Zoladex and Casodex AstraZeneca marketed GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex) GnRH receptor (Zoladex); androgen receptor (Casodex)
Clascoterone 5% solution Clascoterone 5% solution Cassiopea SpA phase 3 Androgen receptor antagonist Androgen receptor (AR)
Abiraterone with Prednisone or Enzalutamide Abiraterone with Prednisone or Enzalutamide Curium US LLC phase 3 CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist class)

  1. Santa Chiara Hospital · 2 drugs in this class
  2. Cassiopea SpA · 2 drugs in this class
  3. The First Affiliated Hospital with Nanjing Medical University · 2 drugs in this class
  4. Pfizer · 2 drugs in this class
  5. Suzhou Kintor Pharmaceutical Inc, · 1 drug in this class
  6. AEterna Zentaris · 1 drug in this class
  7. University of Sydney · 1 drug in this class
  8. CHU de Quebec-Universite Laval · 1 drug in this class
  9. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  10. Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo with enzalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-with-enzalutamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: